{"filing":{"accession_number":"0001213900-26-110477","cik":"0001410098","ticker":"CRMD","company_name":"CorMedix Inc.","form":"8-K","filing_date":"2026-10-19","report_date":"2026-10-19","primary_document":"ea0308957-8k_cormedix.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390026110477/ea0308957-8k_cormedix.htm"},"events":[{"id":35956,"run_id":33145,"accession_number":"0001213900-26-110477","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"CorMedix announced FDA acceptance for Priority Review of a supplemental NDA for REZZAYO for a new indication (prophylaxis of invasive fungal disease), supported by positive Phase III ReSPECT trial results. This is a material regulatory milestone for a biopharmaceutical company's product development pipeline, affecting investor assessment of the company's commercial prospects and product portfolio expansion. While not a traditional earnings release or M\u0026A event, this represents a significant operational/regulatory achievement that would influence a reasonable investor's view of the company's trajectory.","company_name":"CorMedix Inc.","ticker":"CRMD","filing_date":"2026-10-19","form":"8-K","submitted_at":null,"items":[{"id":40196,"accession_number":"0001213900-26-110477","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"CorMedix announced FDA acceptance for Priority Review of a supplemental NDA for REZZAYO for a new indication (prophylaxis of invasive fungal disease), supported by positive Phase III ReSPECT trial results. This is a material regulatory milestone for a biopharmaceutical company's product development pipeline, affecting investor assessment of the company's commercial prospects and product portfolio expansion. While not a traditional earnings release or M\u0026A event, this represents a significant operational/regulatory achievement that would influence a reasonable investor's view of the company's trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T12:01:58.481984+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40196,"accession_number":"0001213900-26-110477","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"CorMedix announced FDA acceptance for Priority Review of a supplemental NDA for REZZAYO for a new indication (prophylaxis of invasive fungal disease), supported by positive Phase III ReSPECT trial results. This is a material regulatory milestone for a biopharmaceutical company's product development pipeline, affecting investor assessment of the company's commercial prospects and product portfolio expansion. While not a traditional earnings release or M\u0026A event, this represents a significant operational/regulatory achievement that would influence a reasonable investor's view of the company's trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T12:01:58.481984+00:00","company_name":"CorMedix Inc.","ticker":"CRMD","filing_date":"2026-10-19"}]}